MRÁZ, Marek, C. ZENT, A. CHURCH, D. JELINEK, Šárka POSPÍŠILOVÁ, S. ANSELL, A. NOVAK, T. WITZIG a G. NOWAKOWSKI. Targeting integrin/CD49D/VLA-4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy. In Haematologica, 15th Congress of the European Hematology Association, Spain, Barcelona, 2010. 2010. ISSN 0390-6078. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{893848, author = {Mráz, Marek and Zent, C. and Church, A. and Jelinek, D. and Pospíšilová, Šárka and Ansell, S. and Novak, A. and Witzig, T. and Nowakowski, G.}, booktitle = {Haematologica, 15th Congress of the European Hematology Association, Spain, Barcelona, 2010.}, language = {eng}, title = {Targeting integrin/CD49D/VLA-4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy}, year = {2010} }
TY - CONF ID - 893848 AU - Mráz, Marek - Zent, C. - Church, A. - Jelinek, D. - Pospíšilová, Šárka - Ansell, S. - Novak, A. - Witzig, T. - Nowakowski, G. PY - 2010 TI - Targeting integrin/CD49D/VLA-4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy ER -
MRÁZ, Marek, C. ZENT, A. CHURCH, D. JELINEK, Šárka POSPÍŠILOVÁ, S. ANSELL, A. NOVAK, T. WITZIG a G. NOWAKOWSKI. Targeting integrin/CD49D/VLA-4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy. In \textit{Haematologica, 15th Congress of the European Hematology Association, Spain, Barcelona, 2010.}. 2010. ISSN~0390-6078.
|